Conferencia online: “La esclerosis múltiple en los próximos 15 años”
Accure Therapeutics presented at ECTRIMS four communications reporting the progress of ACT-01 neuroprotective therapy for Multiple Sclerosis
Webinars on Neuroprotection for Brain Diseases Program
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy
Accure Therapeutics appoints Dr. Rossella Medori as chief medical officer
Accure Therapeutics strengthens scientific advisory board by appointing top-class scientists
Accure Therapeutics launches with €7.6M Series A round
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis
